×
SEQUOIA Trial

SEQUOIA Trial

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration.

Patients are randomised to 12, 8 or 4 weekly treatment.

Trial registry no: NCT02462486

Need any help?

If you would like to know more about us, or want to make an appointment, please don’t hesitate to get in touch.

Request an appointment